PT100997A - Processo para preparacao de composicoes farmaceuticas uteis para a reducao ou o tratamento de pereturbacoes da microcirculacao provocadas pela administracao de meios de contraste para raios x, nmr ou ultrassons por incorporacao de derivados de prostaciclinas - Google Patents

Processo para preparacao de composicoes farmaceuticas uteis para a reducao ou o tratamento de pereturbacoes da microcirculacao provocadas pela administracao de meios de contraste para raios x, nmr ou ultrassons por incorporacao de derivados de prostaciclinas

Info

Publication number
PT100997A
PT100997A PT100997A PT10099792A PT100997A PT 100997 A PT100997 A PT 100997A PT 100997 A PT100997 A PT 100997A PT 10099792 A PT10099792 A PT 10099792A PT 100997 A PT100997 A PT 100997A
Authority
PT
Portugal
Prior art keywords
nmr
contrast media
pereturbaces
ultrasounds
microcirculation
Prior art date
Application number
PT100997A
Other languages
English (en)
Other versions
PT100997B (pt
Inventor
Rainer Klopp
Wolfgang Niemer
Wolfgang Schippel
Werner Krause
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PT100997A publication Critical patent/PT100997A/pt
Publication of PT100997B publication Critical patent/PT100997B/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT100997A 1991-10-22 1992-10-22 Processo para preparacao de composicoes farmaceuticas uteis para a reducao ou o tratamento de pereturbacoes da microcirculacao provocadas pela administracao de meios de contraste para raios x, nmr ou ultrassons por incorporacao de derivados de prostaciclinas PT100997B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4135193A DE4135193C1 (pt) 1991-10-22 1991-10-22

Publications (2)

Publication Number Publication Date
PT100997A true PT100997A (pt) 1994-01-31
PT100997B PT100997B (pt) 1999-10-29

Family

ID=6443371

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100997A PT100997B (pt) 1991-10-22 1992-10-22 Processo para preparacao de composicoes farmaceuticas uteis para a reducao ou o tratamento de pereturbacoes da microcirculacao provocadas pela administracao de meios de contraste para raios x, nmr ou ultrassons por incorporacao de derivados de prostaciclinas

Country Status (11)

Country Link
US (1) US5814301A (pt)
EP (1) EP0609336B1 (pt)
JP (1) JPH07500585A (pt)
AT (1) ATE162718T1 (pt)
CA (1) CA2121838A1 (pt)
DE (2) DE4135193C1 (pt)
DK (1) DK0609336T3 (pt)
ES (1) ES2114570T3 (pt)
GR (1) GR3026324T3 (pt)
PT (1) PT100997B (pt)
WO (1) WO1993007875A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
CN1209751A (zh) * 1996-01-25 1999-03-03 舍林股份公司 血管内使用的改进的浓缩注射液和输注液
CA2312729C (en) * 1997-11-14 2006-05-23 United Therapeutics Corporation Use of 9-deoxy-2', 9-.alpha.-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
CN1319011A (zh) * 1999-06-14 2001-10-24 东丽株式会社 药物在肿瘤组织蓄积的增强剂
US20020147223A1 (en) * 1999-06-14 2002-10-10 Hiroshi Maeda Agent for enhancing accumulation of drugs in tumor tissues
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
DE602005020269D1 (de) * 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
CA3125504C (en) 2013-03-14 2023-10-24 United Therapeutics Corporation Solid forms of treprostinil
EP3849560A4 (en) * 2018-09-14 2022-06-08 Pharmosa Biopharm Inc. PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF WEAK ACID DRUGS AND THEIR USES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3204443A1 (de) * 1982-02-08 1983-08-18 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3427797A1 (de) * 1984-07-25 1986-02-06 Schering AG, 1000 Berlin und 4709 Bergkamen Zytoprotektive wirkung von prostacyclin-derivaten an leber, bauchspeicheldruese und niere
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
US4955878A (en) * 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
SE459806B (sv) * 1987-11-23 1989-08-07 Nils Enar Nilsson Anordning foer foerflyttning av en foersta del relativt en andra del
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤

Also Published As

Publication number Publication date
JPH07500585A (ja) 1995-01-19
GR3026324T3 (en) 1998-06-30
PT100997B (pt) 1999-10-29
EP0609336A1 (de) 1994-08-10
ES2114570T3 (es) 1998-06-01
DK0609336T3 (da) 1998-09-21
ATE162718T1 (de) 1998-02-15
WO1993007875A1 (de) 1993-04-29
US5814301A (en) 1998-09-29
CA2121838A1 (en) 1993-04-29
DE59209175D1 (de) 1998-03-05
EP0609336B1 (de) 1998-01-28
DE4135193C1 (pt) 1993-03-11

Similar Documents

Publication Publication Date Title
ATE202076T1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
YU69991A (sh) Derivati piridina
KR950703965A (ko) 외상 손상과 관련된 신경학적 병변의 치료에서 라모트리진의 적용(application of lamotrigine in the treatment of neurological lesions related to traumatic injuries)
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
PT100997A (pt) Processo para preparacao de composicoes farmaceuticas uteis para a reducao ou o tratamento de pereturbacoes da microcirculacao provocadas pela administracao de meios de contraste para raios x, nmr ou ultrassons por incorporacao de derivados de prostaciclinas
BG101118A (en) Therapeutical compounds
ATE179976T1 (de) Neue 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazol-derivate
NO306400B1 (no) N-substituerte azabicykloheptan-derivater, anvendelse derav og farmasöytisk preparat
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
HUT50325A (en) Process for producing bisphenylalkyl piperazine derivatives and pharmaceutical compositions comprising same as active ingredient
DE59203771D1 (de) 9-substituierte bicyclo [3.3.0]octan-derivate verwendbar als txa2-antagonisten.
DE69600272D1 (de) Chinolin-4-carbonylguanidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
IL105122A0 (en) Benzimidazole derivative for use as an anti-irritant
NO950177L (no) Farmakologisk aktive erivater
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제
ATE155791T1 (de) Etoposid-derivate, ihre herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
DK0660825T3 (da) Antiinflammatoriske makrolactamer (cyclamenol)
ES2123796T3 (es) Derivados de acidos fosfono-succinicos y su utilizacion como medicamentos.

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930701

FG3A Patent granted, date of granting

Effective date: 19990730

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20010131